GlassScriptPhysician profile
Shaun T Cumm
NPI 1669476065
$2,819.38
in general payments reported to CMS, 2019-2025
22 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.61 · 2022: $198 · 2023: $807 · 2024: $1,075 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $412.70 | 2022-2025 | |
| Abbott Laboratories | $287.78 | 2021-2025 | Jot Dx, Cardiomems, Gallant |
| E.R. Squibb & Sons, L.L.C. | $276.02 | 2023-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $268.62 | 2024-2025 | Barostim Neo System |
| Baxter Healthcare | $235.77 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $233.55 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.46 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $143.69 | 2023-2025 | Verquvo |
| Edwards Lifesciences Corporation | $129.60 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.74 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $88.30 | 2024-2025 | |
| Medicomp INC | $81.40 | 2023-2025 | Telepatch Cardiac Monitor |
| Amgen INC. | $81.38 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $52.28 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $49.11 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $42.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $42.73 | 2023 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $31.67 | 2023 | Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $23.30 | 2023 | Arcalyst |
| Ionis Pharmaceuticals, INC. | $20.63 | 2025 | Tryngolza |
| Novo Nordisk INC | $15.87 | 2025 | Wegovy |
| Boston Scientific Corporation | $14.91 | 2025 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Cumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.